ArticleInternational journal of environmental research and public health2021
Adverse Drug Reaction Reporting by Patients in 12 European Countries.
Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors associated with underreporting of adverse drug reactions by patients: a systematic review.International journal of clinical pharmacy · 2023Pooled it
- Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway.British journal of clinical pharmacology · 2026Article
- Resistance, Ineffectiveness, and Off-Label Use Related to Cephalosporins from the Reserve Group-A Pharmacovigilance Signal Detection Study on EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Strengthening pharmacovigilance through patient reporting: a scoping review of awareness, barriers, and facilitators.Journal of pharmaceutical policy and practice · 2026Review
- Safety assessment for ibuprofen using disproportionality analysis: a decade of data from the Romanian national pharmacovigilance system.Frontiers in pharmacology · 2026Article
- Part 1 - imidazolines and the changing face of nasal decongestants.Frontiers in pharmacology · 2025Review
- Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess.Frontiers in pharmacology · 2025Article
- Article
- Article
- Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.Journal of clinical medicine · 2024Review
- Does the risk of hypersensitivity reactions to iopromide differ by sex, race, or across regions/countries? An analysis of 152 233 patients from 4 observational studies and the company's pharmacovigilance database.The British journal of radiology · 2024Article
- Comparing patient reported and medical record data of adverse drug reactions to anti-seizure drugs.International journal of clinical pharmacy · 2024Article
- PHARMACOVIGILANCE IN SERBIA: A TEN-YEAR PHARMACOEPIDEMIOLOGIC ANALYSIS.Acta clinica Croatica · 2023Article
- Awareness, Actions, and Predictors of Actions on Adverse Drug Reaction Reporting among Patients Attending a Referral Hospital in Southern Highland Tanzania.Advances in pharmacological and pharmaceutical sciences · 2023Article
- The effect of clinical pharmacists' intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series.BMC health services research · 2022Article
- Adverse drug reaction reporting for more than a decade: The need for pharmacovigilance policy implementation in Turkey.Journal of Taibah University Medical Sciences · 2022Article
- The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.International journal of environmental research and public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients who report suspected adverse drug reactions (ADRs) help minimize drug safety risks and bolster the pharmacovigilance system. The aim of this study was to examine the contribution of patients to pharmacovigilance and compare the tools used to promote patient reporting in European countries that implemented this reporting type in 2012-2013. A web-based questionnaire was sent to the national competent authorities (NCAs) of the European countries. The received answers were systematized and compared using statistical analysis. The performed statistical analysis demonstrated that changes in the number of received ADR reports increased significantly in each country during the analyzed period. These changes were significantly different in Ireland and Finland from those in the other reviewed countries. The common source of information on direct patient reporting was the country's NCA website. Other sources used were social media pages, leaflets, and posters. This is the first study on patient reporting schemes implemented after the significant reform of the European regulatory system for pharmacovigilance. However, some countries did not actively promote their patient reporting schemes. Our findings indicate that countries with minimal experience in pharmacovigilance systems that include direct patient reporting should organize comprehensive campaigns on ADR reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.